Pharmacokinetic-pharmacodynamic modeling of unboosted atazanavir in a cohort of 1 stable HIV-infected patients

7 1 Service Pharmaceutique – Groupement Hospitalier de Gériatrie, 2 Service de Maladies 8 Infectieuses et Tropicales, 3 Laboratoire de Biochimie et Biologie Moléculaire UF de 9 Pharmacologie Spécialisée, Groupement Hospitalier E. Herriot, 4 Service Pharmaceutique, 10 Groupement Hospitalier Nord, and 5 Service d’Immunologie Clinique, Hospices Civils de 11 Lyon, Lyon, France 12 6 Université Claude Bernard Lyon 1, Lyon, France 13 7 Laboratoire de Biométrie et Biologie Evolutive, UMR CNRS 5558, Villeurbanne, France 14 8 INSERM U851, Immunité, Infection, Vaccination, Lyon, France 15

[1]  C. Torti,et al.  Unboosted Atazanavir for Treatment of HIV Infection , 2012, Drugs.

[2]  R. Porcher,et al.  Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. , 2011, The Journal of antimicrobial chemotherapy.

[3]  R. Kuchenbecker,et al.  Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. , 2011, Annals of internal medicine.

[4]  A. Lazzarin,et al.  Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen , 2010, Antiviral therapy.

[5]  K. Squires,et al.  Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients , 2010, AIDS.

[6]  E. Gianelli,et al.  Efficacy and safety of boosted and unboosted atazanavir‐containing antiretroviral regimens in real life: results from a multicentre cohort study , 2010, HIV medicine.

[7]  R. Savic,et al.  Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and Solutions , 2009, The AAPS Journal.

[8]  C. Solas,et al.  Population Pharmacokinetics of Atazanavir in Human Immunodeficiency Virus-Infected Patients , 2008, Therapeutic drug monitoring.

[9]  P. Colson,et al.  The Genotypic Inhibitory Quotient: A Predictive Factor of Atazanavir Response in HIV-1-Infected Treatment-Experienced Patients , 2008, Journal of acquired immune deficiency syndromes.

[10]  B. Clotet,et al.  Monitoring Atazanavir Concentrations With Boosted or Unboosted Regimens in HIV-Infected Patients in Routine Clinical Practice , 2007, Therapeutic drug monitoring.

[11]  F. de Wolf,et al.  Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice. , 2007, The Journal of antimicrobial chemotherapy.

[12]  D. Breilh,et al.  Virological Responses to Atazanavir–Ritonavir-Based Regimens: Resistance-Substitutions Score and Pharmacokinetic Parameters (Reyaphar Study) , 2005, Antiviral therapy.

[13]  Stuart L. Beal,et al.  Ways to Fit a PK Model with Some Data Below the Quantification Limit , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[14]  L. Sheiner,et al.  Evaluating Pharmacokinetic/Pharmacodynamic Models Using the Posterior Predictive Check , 2001, Journal of Pharmacokinetics and Pharmacodynamics.

[15]  J. Bilello,et al.  Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. , 2001, The Journal of infectious diseases.

[16]  David Roth,et al.  A simplified equation to predict glomerular filtration rate from serum creatinine , 2000 .

[17]  J. Concato,et al.  A simulation study of the number of events per variable in logistic regression analysis. , 1996, Journal of clinical epidemiology.

[18]  A. Buse.  The Likelihood Ratio, Wald, and Lagrange Multiplier Tests: An Expository Note , 1982 .

[19]  Huldrych F. Günthard,et al.  Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. , 2012, JAMA.